Literature DB >> 3807961

Early deposition of aluminum in bone in diabetic patients on hemodialysis.

D L Andress, J B Kopp, N A Maloney, J W Coburn, D J Sherrard.   

Abstract

Aluminum-associated bone disease is a special problem in uremic patients on hemodialysis. We have observed this disorder in uremic patients with insulin-dependent diabetes soon after the start of dialysis treatments. We therefore studied bone biopsy specimens from 18 diabetic patients on hemodialysis to determine whether aluminum accumulates on bone surfaces at an accelerated rate in diabetes. We also measured the rates of bone formation, because lower rates may enhance the accumulation of aluminum on bone surfaces. As compared with 18 nondiabetic controls with uremia who were matched for age and duration of dialysis, the patients with diabetes had a higher rate of aluminum accumulation on bone surfaces (2.1 +/- 0.7 vs. 0.4 +/- 0.2 percent per month, P less than 0.01) and a lower rate of bone formation (117 +/- 50 vs. 396 +/- 81 microns 2 per square millimeter per day, P less than 0.01). Also, the patients with diabetes whose cumulative aluminum intake exceeded 0.5 kg had higher serum aluminum levels after an infusion of deferoxamine, as compared with controls matched for aluminum intake (P less than 0.01). These measurements reflected a higher aluminum content in the whole body in patients with diabetes. We suggest that the enhanced rate of aluminum accumulation on bone surfaces in uremic patients with diabetes occurs as a result of a low rate of bone formation and an increased accumulation of aluminum in the whole body.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3807961     DOI: 10.1056/NEJM198702053160602

Source DB:  PubMed          Journal:  N Engl J Med        ISSN: 0028-4793            Impact factor:   91.245


  5 in total

1.  Acute epidemic aluminium osteomalacia secondary to water supply contamination.

Authors:  A A O'Brien; D P Moore; J A Keogh
Journal:  Ir J Med Sci       Date:  1990-03       Impact factor: 1.568

2.  Calcium carbonate as a phosphate binder in dialysis patients: evaluation of an enteric-coated preparation and effect of additional aluminium hydroxide on hyperaluminaemia.

Authors:  T H Ittel; C Schäfer; H Schmitt; U Gladziwa; H G Sieberth
Journal:  Klin Wochenschr       Date:  1991-01-22

3.  Aluminium osteomalacia in chronic renal failure patients neither on dialysis nor taking aluminium containing phosphate binders.

Authors:  A A O'Brien; D P Moore; J A Keogh
Journal:  Ir J Med Sci       Date:  1990-03       Impact factor: 1.568

Review 4.  Recent developments in aluminum toxicology.

Authors:  F S Monteagudo; M J Cassidy; P I Folb
Journal:  Med Toxicol Adverse Drug Exp       Date:  1989 Jan-Feb

5.  Long-term L-carnitine administration reduces erythropoietin resistance in chronic hemodialysis patients with thalassemia minor.

Authors:  Biagio R Di Iorio; Pasquale Guastaferro; Nicola Cillo; Emanuele Cucciniello; Vincenzo Bellizzi
Journal:  Drug Target Insights       Date:  2007-01-24
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.